MOTIVATION LETTER The Conjunctive Consolidation Threshold model proposes that reward-memory encoding in addiction requires simultaneous activation of three distinct neural circuits: dopaminergic salience, glutamatergic plasticity, and cholinergic gating. My pre-registered computational validation, using ODE/RK45 and Bayesian MCMC on simulated population dynamics, demonstrated an 85.8 percent reduction in encoding probability from 0.855 to 0.122, with super-additivity of 12.8 percentage points when all three circuits are targeted. These results, published as three sole-authored preprints on OSF and Zenodo, and currently under review at Neuroscience and Biobehavioral Reviews, provide the theoretical foundation for a clinical trial. The COMBINE programme requires multidisciplinary collaboration and bold innovation. My framework integrates computational neuroscience, Bayesian statistics, topological data analysis, and clinical pharmacology. I have built three operational platforms: IMPRINT for addiction-liability screening, TOPOLOGIX for drug-protein interaction analysis using persistent homology and bipartite simplicial complexes, and GATE for BCI neural-stimulation safety evaluation. These tools are ready for deployment in a clinical trial context. I seek a US-based principal investigator at an institution such as the University of Michigan or Harvard University, where my endorsers Kent Berridge, Samuel Gershman, and Nathaniel Daw are faculty. I would contribute the CCT theoretical framework, the Bayesian trial architecture specified in my Zenodo preprint, and the computational infrastructure for real-time data analysis. The clinical trial would test a triple-combination pharmacotherapy targeting dopamine D1 receptors, NMDA receptors, and alpha7 nicotinic acetylcholine receptors in a randomized controlled design with 120 participants across two sites, one in the United States and one in Lagos, Nigeria. The Africa-to-global health angle is central. Nigeria has an estimated 14.4 million people living with substance use disorders and fewer than 200 psychiatrists. A low-cost, scalable pharmacotherapy validated through this trial could be deployed through the existing primary healthcare network. My experience as a PCN-licensed pharmacist and National Product Manager at Synthcare gives me direct knowledge of drug supply chains in West Africa. I am not yet enrolled in a graduate programme. I will apply for an MSc in Computational Neuroscience at the Medical University of Graz, Austria, starting October 2026. The COMBINE grant would fund my independent research contributions and support travel between Lagos and the US-based PI laboratory. My provisional patent on the CCT core architecture, filed Q3 2026, protects the intellectual property for future licensing. RESEARCH STATEMENT The Conjunctive Consolidation Threshold model addresses a fundamental gap in addiction neuroscience: why single-target pharmacotherapies for substance use disorders show limited efficacy and high relapse rates. Current models treat reward-memory encoding as a linear process driven primarily by dopamine. The CCT model posits that memory consolidation requires the simultaneous crossing of three independent thresholds: a dopamine salience threshold, an NMDA-dependent plasticity threshold, and a cholinergic gating threshold. No single circuit is sufficient; all three must be activated concurrently. My computational validation used a system of coupled ordinary differential equations solved with RK45 integration, parameterized from published electrophysiological data on ventral tegmental area dopamine neurons, hippocampal CA1 NMDA receptors, and basal forebrain cholinergic projections. The Bayesian MCMC analysis, implemented in PyMC with 10,000 samples across four chains, confirmed all five pre-registered hypotheses H1 through H5. The key finding: triple-target intervention reduces encoding probability from 0.855 to 0.122, a reduction of 85.8 percent, while dual-target combinations produce at most 42.3 percent reduction. The super-additivity of 12.8 percentage points indicates a genuine nonlinear interaction, not merely additive effects. The proposed clinical trial would test this model in human participants with alcohol use disorder, the most prevalent substance use disorder in both the United States and Nigeria. The trial design follows the Bayesian adaptive framework specified in my Zenodo preprint. Participants would be randomized to one of four arms: placebo, low-dose triple combination, medium-dose triple combination, and high-dose triple combination. The primary endpoint is cue-induced craving reduction at 12 weeks, measured by the Alcohol Urge Questionnaire. Secondary endpoints include days of abstinence, relapse rate at 24 weeks, and changes in resting-state functional connectivity between the ventral striatum, hippocampus, and insula. The computational infrastructure for this trial already exists. IMPRINT screens participants for addiction liability using a 15-minute behavioral task analyzed with Bayesian hierarchical modeling. TOPOLOGIX, using persistent homology and bipartite simplicial complexes, will analyze drug-protein interaction networks for off-target effects and potential cardiotoxicity, building on my hERG cardiotoxicity MVP. GATE provides a safety evaluation framework for any concurrent neural-stimulation protocols. My topological data analysis skills, implemented through Ripser and Gudhi, allow me to identify nonlinear patterns in high-dimensional neural data that conventional methods miss. The bipartite simplicial complex approach maps drug-protein interactions as topological features, revealing binding patterns that correlate with clinical outcomes. This method has been validated on the hERG cardiotoxicity dataset with an AUROC of 0.634, which I am improving through feature engineering and ensemble methods. The Africa component is not an afterthought. Lagos has a catchment population of 24 million people with a high burden of alcohol use disorder and limited treatment access. The trial would include a satellite site at the Lagos University Teaching Hospital, where I have existing collaborations through my work at the Centre for Drug Discovery, Development and Production. The Bayesian adaptive design allows for interim analyses and dose adjustments, reducing the sample size required and making the trial feasible in a resource-limited setting. My provisional patent on the CCT core architecture, filed Q3 2026, covers the computational method for identifying conjunctive consolidation thresholds and the triple-combination dosing algorithm. This intellectual property provides a pathway to clinical translation and potential licensing to pharmaceutical companies developing addiction therapies. BIOGRAPHICAL SKETCH Eniola Ayodele Olutogun earned a B.Pharm from the University of Ibadan in 2021 with a CGPA of 5.1 out of 7.0, equivalent to a German grade of 1.9. He is a licensed pharmacist with the Pharmacists Council of Nigeria. His undergraduate research focused on NMDA receptor docking studies with insulin at the Centre for Drug Discovery, Development and Production, and antimicrobial resistance genomics at the Global Health Research Unit on Genomic Surveillance of Antimicrobial Resistance. Since 2025, he has conducted independent research on the Conjunctive Consolidation Threshold model, producing three sole-authored preprints. The foundational paper on OSF (DOI 10.17605/OSF.IO/KG7B5) introduces the tripartite framework. The formal mathematical specification (DOI 10.17605/OSF.IO/EMY4U) provides the differential equations and parameter estimation. The Bayesian population dynamics and clinical trial architecture (Zenodo DOI 10.5281/zenodo.20492472) presents the adaptive trial design and power analysis. A review article is under review at Neuroscience and Biobehavioral Reviews. A co-authored paper on alcohol use disorder mechanisms is under review at Alcohol (Elsevier). He has built three computational platforms. IMPRINT screens for addiction liability using Bayesian hierarchical models. TOPOLOGIX applies topological data analysis to drug-protein interactions, using persistent homology and bipartite simplicial complexes. GATE evaluates safety of BCI neural-stimulation protocols and is released under Apache 2.0 license. His computational skills include Python with scipy, numpy, PyMC for MCMC, and ODE solvers; R for statistical analysis; topological data analysis with Ripser and Gudhi; neural simulation with NEURON and Brian2; structural biology with AlphaFold, RDKit, ADMET and QSAR tools, GROMACS, and AutoDock; workflow management with Nextflow and SLURM; and database management with Supabase and PostgreSQL. He has received endorsements on arXiv from Samuel Gershman at Harvard University. Kent Berridge at the University of Michigan, Nathaniel Daw at Princeton University, and Marcelo Mattar at New York University have reviewed and commented on his preprints. A provisional patent on the CCT core architecture was filed in Q3 2026. His employment includes National Product Manager at Synthcare since March 2026, Clinical Pharmacist at Ramset Pharmacy from January to March 2026, Research Assistant at the Centre for Drug Discovery, Development and Production, and Bioinformatics Researcher at the Global Health Research Unit on Genomic Surveillance of Antimicrobial Resistance. He is applying for MSc programmes in Computational Neuroscience starting October 2026, with the Medical University of Graz in Austria as the primary target. BUDGET NARRATIVE The proposed budget supports a 36-month clinical trial with two sites: a US-based lead institution and a satellite site in Lagos, Nigeria. Total direct costs are estimated at USD 487,000. Personnel: USD 192,000. The US-based principal investigator receives 10 percent effort at USD 24,000 per year for three years. A US-based postdoctoral fellow at 50 percent effort receives USD 60,000 per year. A Lagos-based clinical coordinator at 100 percent effort receives USD 18,000 per year. A Lagos-based research nurse at 100 percent effort receives USD 12,000 per year. A data analyst at 50 percent effort receives USD 30,000 per year. Equipment: USD 45,000. Two laptop workstations for data analysis at USD 3,000 each. One server for computational modeling and TDA at USD 15,000. EEG equipment for neural monitoring at USD 24,000. Supplies: USD 120,000. Study medication costs for 120 participants at 12 weeks per participant, including placebo, at USD 800 per participant, total USD 96,000. Laboratory supplies for blood draws and biomarker analysis at USD 200 per participant, total USD 24,000. Travel: USD 60,000. Four round-trip flights between Lagos and the US site for the applicant at USD 3,000 each, total USD 12,000. Two trips for the US-based PI to Lagos for site initiation and monitoring at USD 5,000 each, total USD 10,000. Participant travel reimbursements at USD 150 per visit for 12 visits across 120 participants, total USD 216,000, capped at USD 38,000. Participant costs: USD 70,000. Participant compensation at USD 50 per visit for 12 visits across 120 participants, total USD 72,000, capped at USD 70,000. Indirect costs: Not included. The applicant is an independent researcher without a US institution. Indirect costs will be negotiated with the host US institution upon award. Total: USD 487,000. CHECKLIST - [ ] Confirm US-based PI partner and obtain letter of support - [ ] Verify COMBINE programme eligibility for independent researchers without US institutional affiliation - [ ] Obtain updated letters of endorsement from Kent Berridge, Samuel Gershman, Nathaniel Daw, and Marcelo Mattar - [ ] Complete NIH biosketch format for Eniola Ayodele Olutogun - [ ] Upload three preprints to NIH Commons or attach as PDFs - [ ] Submit provisional patent application number and filing date - [ ] Obtain letter of collaboration from Lagos University Teaching Hospital - [ ] Complete human subjects research training certification (CITI Program) - [ ] Prepare data management and sharing plan per NIH policy - [ ] Verify that the Bayesian adaptive trial design meets NIH data safety monitoring board requirements - [ ] Confirm that the ODE/RK45 and Bayesian MCMC validation code is publicly accessible on GitHub - [ ] Submit budget justification in NIH format with detailed cost breakdown - [ ] Obtain IRB approval or letter of exemption from US host institution - [ ] Verify that the COMBINE programme accepts applications with non-US co-investigators as subcontracts - [ ] Prepare a facilities and resources statement for the Lagos site EDITOR NOTES - Eligibility risk: The COMBINE programme requires a US-based PI as the lead applicant. Eniola is an independent researcher without US institutional affiliation. He must secure a US-based PI before submission, ideally at University of Michigan or Harvard. The letter of support from this PI is the single most critical document. - Fact verification needed: The provisional patent filing date is listed as Q3 2026. If the application deadline is before Q3 2026, the patent will not yet be filed. Confirm the actual filing status and adjust the narrative accordingly. If not filed, remove all patent references. - Gap in profile: The applicant has not yet enrolled in a graduate programme. The COMBINE programme may require a doctoral degree or enrollment in a PhD programme for the PI role. Eniola can only serve as a co-investigator or consultant. The budget narrative should reflect this by listing his role as consultant or independent contractor, not PI. - Missing detail: The budget narrative assumes a US-based host institution but does not name one. The applicant must identify a specific US institution and obtain a letter of commitment before submission. The indirect cost rate will depend on the host institution's negotiated rate. - Timeline risk: The applicant is applying for MSc programmes starting October 2026. If the COMBINE grant is awarded for a 36-month period starting in 2026, the applicant will be simultaneously enrolled in an MSc programme and conducting the trial. This dual commitment may raise concerns about time allocation. Address this in the application by specifying that the MSc programme is in computational neuroscience and directly supports the trial's data analysis aims.